Participated · Series B · Jan 2023

Property Meld is a stand-alone property maintenance software platform founded in 2015 and based in Rapid City, S.D. Its core product centralizes maintenance scheduling, communication, coordination, billing, and oversight to reduce maintenance costs and improve renter satisfaction. The platform integrates with AppFolio, Buildium, Propertyware, and RentManager and is used by industry operators including Evernest, HomeRiver Group, PURE Property Management, Real Property Management, All County, and PMI franchises. Property Meld serves over 650 customers and covers more than 450,000 units. In January 2023 the company raised $15 million in a Series B led by Frontier Growth, bringing total funding to $22 million. The company says the proceeds will support continued growth and product expansion to further optimize maintenance for property managers.

Participated · Series A · Oct 2021

Query.AI provides a patented, browser-based security investigations control platform that delivers real-time access and centralized insights across on-premises, multi-cloud, and SaaS applications without duplicating data. The platform is aimed at modern enterprises seeking consolidated investigation workflows. The company is led by founder and CEO Dhiraj Sharan and is based in Brookings, South Dakota. Query.AI intends to use the new funding to scale product development and customer growth. Financially, the company completed a $15M Series A round. The product emphasizes integration across native data locations to avoid data duplication. Query.AI offers a patented, browser‑based security investigations control plane that normalizes and enriches data across platforms (including SIEM, SOAR, and XDR) to enable faster investigations without duplicating data. The platform uses a privacy‑by‑design approach and supports guided data exploration and natural language processing so analysts need not be experts in individual systems. Query.AI pulls data where it lives via vendor APIs, reducing the need to index or transfer data and helping lower costs tied to data ingestion. The company was founded by Dhiraj Sharan and Andrew Maloney, former engineering and product leaders from Niara and JASK, and is backed by the founders of ArcSight, CipherCloud, and Verodin. Customers such as Fox Corporation and Hogan Lovells report faster, higher‑confidence incident response after federating investigations through the platform. Query.AI plans to use its seed funding to scale go‑to‑market and engineering teams to meet demand.

Participated · Series B · Jul 2020

SAB Biotherapeutics is a clinical-stage biopharma developing a proprietary platform to rapidly produce fully human polyclonal antibody immunotherapies at commercial scale without human plasma donors. Its lead candidate, SAB-185, is an anti‑SARS‑CoV‑2 fully human polyclonal antibody therapeutic poised to begin clinical trials. The company’s platform is being applied across infectious disease, autoimmune, inflammation and oncology programs. SAB has secured program-specific funding from BARDA (up to $9.4M) and operates under a $27M Rapid Response contract with the DoD JPEO‑CBRND. With the newly closed Series B, SAB reports approximately $50M in equity raised and more than $100M in non-dilutive grants and contracts since founding. The company is working with partners to accelerate delivery of its immunotherapy platform in response to COVID‑19 and other indications. SAB Biotherapeutics is a clinical-stage biopharmaceutical company developing fully human immunotherapies using its DiversitAb™ platform to produce fully human immunoglobulins outside of humans. The platform is described as scalable and dynamic, enabling large-scale production with shorter development cycles than current methods. SAB is focused on targets across cancer, autoimmune diseases and infectious diseases, including influenza and Type 1 diabetes. The company plans to use the new capital to accelerate growth, expand operations and advance its immunotherapy platform toward commercial targets. SAB is progressing clinical development and intends to proceed to Phase 2 clinical trials. Since 2014 the company has developed immunotherapies against more than a dozen targets, achieved 100% efficacy in pre-clinical testing and completed successful Phase 1 clinical trials. It has also secured substantial grants, contracts and in-kind services from BARDA and the NIH. SAB Biotherapeutics develops antibody therapeutics using its DiversitAb™ Platform, which leverages transchromosomic cattle (Tc Bovine™) engineered to produce fully human immunoglobulin G antibodies. The company is clinical-stage and focuses on both the science and large-scale manufacturing of antibody products. Its platform is being applied to infectious diseases, including influenza, with potential relevance to public health threats, rare conditions, and long-term diseases. SAB partnered with the University of South Dakota Sanford School of Medicine on the influenza program and engaged through the BioSNTR distributed research initiative. The company is led by President and CEO Eddie Sullivan, Ph.D. Financially, the company received a Small Business Innovation Research award to support production and preclinical testing of its influenza antibody candidate.

Led · Series C · Apr 2019

Inanovate develops blood tests that detect antibodies associated with breast cancer and other diseases. Its core product under development is a breast cancer blood test intended to identify false positives from screening mammograms and reduce unnecessary follow-up imaging. The company analyzes blood draws using its patented BioID-800 biomarker analysis platform, a compact, fully automated benchtop machine that uses disposable test cartridges. Inanovate is also developing a second test to monitor breast cancer patients through therapy and to detect recurrence at an earlier, more treatable stage. Led by CEO David Ure, the company operates in Raleigh, N.C., and Sioux Falls, South Dakota. Recent non-dilutive and partnership support includes a $2.0M Phase 2 SBIR grant from the National Cancer Institute and a licensing and collaboration agreement with Sanford Health for biomarker IP and patient/sample access.